PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition
- 29 September 2020
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 117 (39), 24427-24433
- https://doi.org/10.1073/pnas.2000060117
Abstract
PIK3CA hotspot mutation is well established as an oncogenic driver event in cancer and its durable and efficacious inhibition is a focus in the development and testing of clinical cancer therapeutics. However, hundreds of cancer-associated PIK3CA mutations remain uncharacterized, their sensitivity to PI3K inhibitors unknown. Here, we describe a series of PIK3CA C-terminal mutations, primarily nucleotide insertions, that produce a frame-shifted protein product with an extended C terminus. We report that these mutations occur at a low frequency across multiple cancer subtypes, including breast, and are sufficient to drive oncogenic transformation in vitro and in vivo. We demonstrate that the oncogenicity of these mutant p110 alpha proteins is dependent on p85 but not Ras association. P110 alpha-selective pharmacologic inhibition blocks transformation in cells and mammary tumors characterized by PIK3CA C-terminal mutation. Taken together, these results suggest patients with breast and other tumors characterized by PIK3CA C-terminal frameshift mutations may derive benefit from p110 alpha-selective inhibitors, including the recently FDA-approved alpelisib.Funding Information
- HHS | NIH | National Cancer Institute (K99 CA204601-01A1)
- EIF | Stand Up To Cancer (SU2C-AACR-DT0209)
This publication has 22 references indexed in Scilit:
- Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanismsNature Medicine, 2011
- Hot-spot mutations in p110α of phosphatidylinositol 3-kinase (PI3K): Differential interactions with the regulatory subunit p85 and with RASCell Cycle, 2010
- A frequent kinase domain mutation that changes the interaction between PI3Kα and the membraneProceedings of the National Academy of Sciences of the United States of America, 2009
- Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanismsProceedings of the National Academy of Sciences of the United States of America, 2008
- The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα MutationsScience, 2007
- Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic SubunitScience, 2007
- Rare cancer-specific mutations in PIK3CA show gain of functionProceedings of the National Academy of Sciences of the United States of America, 2007
- The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformationProceedings of the National Academy of Sciences of the United States of America, 2006
- The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cellsProceedings of the National Academy of Sciences of the United States of America, 2005
- High Frequency of Mutations of the PIK3CA Gene in Human CancersScience, 2004